Aldosterone Blockade: Benefit Depends on the Setting

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Potential long-term benefit must be weighed against hyperkalemia and other adverse effects. Monitoring is part of treatment, not an optional extra.

Aldosterone affects kidney salt handling and the heart. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Aldosterone affects kidney salt handling and the heart. Aldosterone signal — Acts through mineralocorticoid receptors; Distal sodium retention — Potassium handling also changes; Cardiovascular effects — Treatment evidence depends on disease phenotype; Receptor blockade and review — Monitor potassium and kidney function. Choose the specific agent for its supported indication and the patient’s eligibility. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Receptor-mediated effects

Mineralocorticoid receptor activation contributes to sodium retention, inflammation, and fibrosis. Blocking this pathway has different evidence across cardiac and kidney populations.

Identify the indication

Heart failure phenotype, resistant hypertension, albuminuric diabetic CKD, and potassium risk determine whether a particular agent is appropriate.

Choose the agent for the studied indication

Spironolactone or eplerenone for appropriate heart-failure or resistant-hypertension indications is a different decision from finerenone for albuminuric diabetic CKD. Review potassium, kidney function, other RAAS drugs, NSAIDs, and supplements before starting; do not substitute agents solely because all block the same receptor.

Plan surveillance before prescribing

For finerenone, measure potassium and kidney function before initiation and reassess potassium at about 4 weeks after starting or changing dose, then periodically. More frequent checks may be needed with illness or interacting drugs. Use the agent-specific eligibility and hold/restart rules.

Interpret trial outcomes accurately

Separate albuminuria changes from hard kidney or cardiovascular outcomes. Confirm that a cited study tested the named drug in the relevant population.

Balance protection and toxicity

Potential long-term benefit must be weighed against hyperkalemia and other adverse effects. Monitoring is part of treatment, not an optional extra.

Supporting evidence

Continue learning